|
Market Closed -
Nasdaq
16:00:00 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 47.13 USD | +2.66% |
|
-5.59% | -32.24% |
Company Valuation: Structure Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,991 | 1,553 | 4,809 | 3,361 | - | - |
| Change | - | -22.02% | 209.65% | -30.11% | - | - |
| Enterprise Value (EV) 1 | 1,991 | 669.4 | 3,362 | 2,394 | 2,802 | 3,359 |
| Change | - | -66.38% | 402.31% | -28.81% | 17.04% | 19.89% |
| P/E | -50.3x | -34.8x | -86.9x | -29.1x | -21.6x | -26.2x |
| PBR | - | 5.39x | 9.75x | 9.26x | 15.5x | 54.2x |
| PEG | 0.6x | 9.4x | -33.89x | -0x | -0.6x | 1.5x |
| Capitalization / Revenue | - | - | - | 87.4x | 80,654x | 24.8x |
| EV / Revenue | - | - | - | 62.2x | 67,234x | 24.8x |
| EV / EBITDA | - | -4.26x | -11.8x | -5.3x | -5.48x | -6.36x |
| EV / EBIT | -19.4x | -4.23x | -11.7x | -5.37x | -5.22x | -7.69x |
| EV / FCF | -24.4x | -5.68x | -14.9x | -6.38x | -7.26x | -7.37x |
| FCF Yield | -4.1% | -17.6% | -6.72% | -15.7% | -13.8% | -13.6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.81 | -0.78 | -0.8 | -1.621 | -2.187 | -1.801 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 38.46 | 0.0417 | 135.7 |
| EBITDA 1 | - | -157.2 | -285.5 | -451.7 | -511.6 | -527.9 |
| EBIT 1 | -102.8 | -158.2 | -286.8 | -445.9 | -536.4 | -436.8 |
| Net income 1 | -89.62 | -122.5 | -141.2 | -308.5 | -475.4 | -339.5 |
| Net Debt 1 | - | -883.5 | -1,446 | -967.2 | -559.2 | -2.073 |
| Reference price 2 | 40.76 | 27.12 | 69.55 | 47.13 | 47.13 | 47.13 |
| Nbr of stocks (in thousands) | 48,855 | 57,261 | 69,139 | 71,310 | - | - |
| Announcement Date | 3/8/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -29.08x | 62.24x | -5.3x | -.--% | 3.36B | |
| 20.2x | 7.1x | 14.34x | 1.44% | 68.21B | |
| 36.48x | 9.51x | 29x | 0.04% | 64.25B | |
| -74.38x | 14.34x | -69.16x | -.--% | 26.54B | |
| -15.61x | 5.93x | -7.46x | -.--% | 25.61B | |
| 27.16x | 5.09x | 16.92x | -.--% | 19.88B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.13B | |
| 1290.27x | 37.31x | 814.28x | -.--% | 14.93B | |
| 17.57x | 5.23x | 12.21x | -.--% | 14.1B | |
| -85.32x | 7.81x | -64.69x | -.--% | 12.45B | |
| Average | 123.67x | 17.28x | 77.71x | 0.18% | 26.65B | |
| Weighted average by Cap. | 79.14x | 11.18x | 49.89x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GPCR Stock
- Valuation Structure Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
